Mayne Pharma

Mayne Pharma will receive up to $4.8 million to expand its advanced manufacturing capability, aiming to double production of chronic pain medications, boost encapsulation capacity from 56 million to 104 million doses per year, and increase blister packaging capacity from 7.9 million to 21.3 million boxes per year.